x
ServiziMenu principaleHome
You are here: Home > Events > Past events > 2015 > ESO Conference Personalised Approach to Prostate Cancer Management
Print

Description

Chairs: K. Touijer, US - R. Valdagni, IT - H. Van Poppel, BE
Honorary Chair: L. Denis, BE
Scientific Coordinator: M.J. Roobol, NL



THE VIDEOBROADCAST OF THE SESSIONS CAN BE VIEWED HERE


THE CONFERENCE

The “Personalized approach to prostate cancer management” ESO Conference will be held on 12 November 2015 in Barcelona in conjunction with the 7th EMUC meeting (European Multidisciplinary meeting on Urological Cancers).
After the two ESO events on predictive models for decision making in prostate cancer, held in Venice in 2008 and in New York City in 2011, the 2015 Conference will focus on the  challenging topic of personalized medicine in prostate cancer.


ORGANISERS
The Conference is organized by the European School of Oncology in conjunction with EMUC15 (European Multidisciplinary meeting on Urological Cancer - details available at emuc15.uroweb.org and under the auspices of Europa Uomo - the European Prostate Cancer Coalition (further information available at www.europa-uomo.org).

The European School of Oncology was founded in 1982 with the aim of contributing to the reduction of deaths from cancer due to late diagnosis and/or inadequate treatment. By improving the skills of all health professionals dealing with cancer patients, ESO helps shorten the time needed to transfer knowledge from research centres to daily practice, combining advanced technology with humanism in care.


CONFERENCE OVERVIEW
This multidisciplinary and multiprofessional conference will provide highlights on the difference aspects of a personalised approach to prostate cancer management in general and, in particular, on:

• The definition of who is at risk
• The prediction in diagnosis (considering genomics, transcriptome sequencing, biomarkers, imaging)
• The single patient’s needs (considering coping with cancer and decision making, life expectancy and comorbidities, the patient’s perspective)
• Making cancer treatment a personalized approach (considering observational programs, surgery, radiotherapy and brachytherapy, medical oncology)
• Rapid learning systems and transforming cancer care through Big Data
• Future trends in research


TARGET AUDIENCE
This conference is directed toward urologists, radiation oncologists, medical physicists, medical oncologists, pathologists, biostatisticians and investigators in outcomes research and genomics.


EDUCATIONAL OBJECTIVES
As a result of attending this activity, participants will be expected:

• To define the state of the art of personalized approach to prostate cancer management
• To determine the future research trends within the oncologic community


The Conference will be held during the:



 

 

.

General information

VENUE
The  Conference will take place at the Palau de Congressos de Catalunya which is easily accessible by public transport. Barcelona has an excellent public transport system connecting all parts of the city.

Palau de Congressos de Catalunya
Av. Diagonal, 661-671
08028 Barcelona Spain
Web: www.pcongresos.com


CONTACTS
The management of the Conference and registration are handled by the official congress organiser:

EMUC Congress Organiser - Congress Consultants B.V.
P.O. Box 30016
6803 AA Arnhem, The Netherlands
Tel: +31 (0) 26 389 1751
Fax + 31 (0) 26 389 1752
Email: emuc2015@congressconsultants.com

For further information on ESO or its Prostate Cancer Programme, please contact:

European School of Oncology
Rita De Martini
Via Turati 29, 20121, Milan (Italy)
rdemartini@eso.net or prostate@eso.net
Tel +39 02 85464527


CERTIFICATE OF ATTENDANCE
The Certificate of attendance related to ESO Conference can be collected via the EMUC website in return of the filled in Evaluation Questionnaire.
The certificate of attendance related to EMUC15  can be collected as of Monday 16 November via EMUC website.


CME ACCREDITATION
The Accreditation Council of Oncology in Europe (ACOE) and the European Accreditation Council for Continuing Medical Education (EACCME) have acknowledged the quality of the scientific programme and its educational value. The Breast Cancer Screening Conference (BCS) has been assigned 6 European Continuing Medical Education Credits (ECMEC).
Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™.
Information on the process to convert EACCME credit to AMA credit can be found at www.amaassn.org/go/internationalcme.


CLOAKROOM/LUGGAGE
A cloakroom is available and is at participants’ disposal during congress hours. Please be sure to collect all personal belongings at the end of the day.


CONGRESS MATERIAL
Each delegate can collect congress material which includes the programme book.


ELECTRICITY
Electricity supply in Barcelona is 220 Volts and the connection is made by a two-pin plug. Please be aware that delegates from the USA will require a voltage converter. Delegates from the United Kingdom will require a plug adapter and this is best bought in the UK as they are hard to find in Barcelona.


INSURANCE
The organisers bear no responsibility for untoward events in relation to the participation in the Conference and participants are advised to take out their own personal and travel insurance coverage.


LANGUAGE
The Conference will be held in English, no translation will be provided.


MOBILE PHONES
The sound and flashlights of mobile phones must be switched off during all sessions.


SAFETY
All bags may be subject to inspection. Security is present for your safety. Please take all personal effects with you when leaving the session rooms.


SMOKING POLICY
Smoking is prohibited inside the congress centre and the exhibition area.





Faculty list


FACULTY
(as of 24 August 2015)
L. Bellardita, Prostate Cancer Program, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
A. Bjartell,  Dept. of Translational Medicine Lund University , Dept. of Urology, Skåne University Hospital, Malmö, SE
A. Bossi, Dept. of Radiation Oncology, Institut Gustave Roussy, Paris, FR
P. Boyle, International Prevention Research Institute – IPRI, Lyon, FR
A. Briganti, Dept. of Urology, Vita-Salute University, San Raffaele Hospital, Milan, IT
F. Claessens, Dept. of Cellular and Molecular Medicine, Molecular Endocrinology Laboratory, University of Leuven, Leuven, BE
F. Demichelis
, Centre for Integrative Biology, University of Trento, Trento, IT
L. Denis,  Oncology Centre Antwerp (OCA), Antwerp, BE
U. Haberkorn, Radiologische Klinik und Poliklinik, University of Heidelberg, Heidelberg, DE
G. Jenster
, Dept. of Urology, Erasmus University Medical Center, Rotterdam, NL
R.J. Karnes
, Dept. of Urology, Mayo Clinic, Rochester, US
K. Mastris, Europa Uomo, Clayhall Ilford Essex, UK
F. Mols, Dept. of Medical and Clinical Psychology, Center of Research on Psychology in Somatic diseases (CoRPS), Tilburg University, Tilburg, NL
C. Moore
, Dept. of Surgical and Interventional Science, University College, London, UK
N. Mottet
, Dept. of Urology, University Hospital, Saint-Etienne Cedex, FR
M.J. Roobol, Dept. of Urology, Erasmus University Medical Center, Rotterdam, NL
C.N. Sternberg,  Dept. Medical Oncology, Ospedale San Camillo, Rome, IT
K. Touijer, Dept. of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, US
R. Valdagni, Radiation Oncology 1, Prostate Cancer Programme, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
H. Van Poppel, Dept. Urology, University Hospital Gasthuisberg, Katholieke Universiteit, Leuven, BE
A. Vickers, Dept. of Biostatistics and Epidemiology, Memorial Sloan-Kettering Cancer Center, New York, US





Programme


12 November

   
8:30
 Welcome
K. Touijer, US - R. Valdagni, IT - H. Van Poppel, BE
8:35 Invited Lecture - Paradigm shifts in prostate cancer
K. Touijer, US
9:05
 Invited Lecture - “Androgen-regulated transcription in prostate cancer”
F. Claessens, BE
 9:35 Who is at risk? Population screening or individualised prediction?
M.J. Roobol, NL
 9:55
 Coffee Break
TOWARDS PREDICTION IN DIAGNOSIS
Chairs: N. Mottet, FR - C. Moore, UK   

10:20
 Genetic /genomic tools
F. Demichelis, IT
10:40
 Transcriptome sequencing
G. Jenster, NL
11:00
 Biomarkers
A. Bjartell, SE
11:20
 Imaging
C. Moore, UK
 11:40
 PSMA ligands for diagnosis and therapy of prostate cancer
U. Haberkorn, DE
 12:10 Discussion
 12:30 Lunch
PERSONALISING HEALTHCARE
Chairs: K. Touijer, US - R. Valdagni, IT
 13:20 The single patient’s needs: Coping with cancer and decision making
L. Bellardita, IT
13:40
 The single patient’s needs:  Life expectancy and comorbidities
A.  Vickers, US
 14:00 The patient’s perspective
K. Mastris, UK
 14:20 Discussion
MAKING CANCER TREATMENT PERSONAL
Chairs: A. Bossi, FR - M.J. Roobol, NL - C.N. Sternberg, IT - H. Van Poppel, BE
 14:40 What do we need in active surveillance?
R. Valdagni, IT
 15:00 

What do we need in surgery?
A. Briganti, IT

 15:20 What do we need in radiotherapy?
A. Bossi, FR
 15:40 Coffee Break
 16:00 What do we need in advanced disease?
C.N. Sternberg, IT
 16:20 What do we need to identify patients who may benefit from adjuvant treatments, targeted therapies and drug sequencing combinations?
R.J. Karnes, US
 16:40
 What do we need about quality of life in long-term survivors?
F. Mols, NL
 17:00 Discussion
 17:15 Rapid learning systems: Transforming cancer care through Big Data
P. Boyle, FR
 17:45 Conclusions

 

Follow us